Meeting
2022 ASCO Annual Meeting
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
Authors
Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
Biagio Ricciuti , Joao Victor Machado Alessi , Yvonne Y. Li , Victor R. Vaz , Federica Pecci , Giuseppe Lamberti , Adriana Paula de Castro Barrichello , Hersh Gupta , Mizuki Nishino , Andrew D. Cherniack , Lynette M. Sholl , Scott J. Rodig , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9021)
DOI
10.1200/JCO.2022.40.16_suppl.9021
Abstract #
9021
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Retrospective analysis of change in frequency of STK11 mutation in lung adenocarcinomas over a 10-year period.
First Author: Deevyashali Parekh
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2022 ASCO Annual Meeting
A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).
First Author: Wafik S. El-Deiry
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang